A 5-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients (FISCO)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Novartis

ClinicalTrials.gov Identifier:

NCT01220115

First received: October 11, 2010

Last updated: May 18, 2015

Last verified: May 2015

History of Changes

Purpose

A long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.

Condition
Sickle Cell Disease


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	A 5-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease Patients

Resource links provided by NLM:

Genetics Home Reference related topics: sickle cell disease

MedlinePlus related topics: Sickle Cell Anemia

Genetic and Rare Diseases Information Center resources: Sickle Cell Anemia

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:

Document current treatment patterns, natural history and outcomes in patients with sickle cell disease [ Time Frame: up to 5 years ]

Secondary Outcome Measures:

Data collection [ Time Frame: up to 5 years ]
Collection of the following data:Current therapies used for the treatment of SCD Current transfusion practices, Difference in treatments between pediatric and adult patients, Use of chelation therapies, Frequency and types of crises including Frequency of hospitalizations, Incidence of end organ damage (caridac, renal, pulmonary,liver), Quality of life assessed by PedsQL TM Pediatric Quality of Life Inventory for patients 2- <18 years old and SF-36® Health Survey for patients 18 years old and older
Measure Sickle cell crisis and hospitalizations [ Time Frame: up to 5 years ]
To evaluate whether patients on regular transfusion protocol have fewer crisis and hospitalizations


Enrollment:	498
Study Start Date:	January 2010
Study Completion Date:	September 2014
Primary Completion Date:	September 2014 (Final data collection date for primary outcome measure)

Groups/Cohorts
No treatment Patients aged 2 to less than 12
No treatment patients aged 12 to less than 18 Patients aged 12 to less than 18
No treatment Patients greater than 18 years patients greater than 18 years

Eligibility


Ages Eligible for Study:	2 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients with Sickle cell disease age 2 years and older

Criteria

Inclusion Criteria:

Male or female patients with HbSS, HbS/beta-thalassemia and HbSC
Age > 2 years old.
Written informed consent by the patient or legal guardians, and pediatric assent where indicated.

Exclusion Criteria:

Patients with Sickle Cell trait (HbAS) are not eligible for the study
Patient or legal guardians unable or unwilling to give consent, or pediatric assent where indicated.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01220115

Show 42 Study Locations

Sponsors and Collaborators

Novartis

Investigators


Study Director:	Novartis Pharmaceuticals	Novartis Pharmaceuticals

More Information


Responsible Party:	Novartis
ClinicalTrials.gov Identifier:	NCT01220115 History of Changes
Other Study ID Numbers:	CICL670AUS38
Study First Received:	October 11, 2010
Last Updated:	May 18, 2015

Keywords provided by Novartis:


sickle cell disease iron over load

Additional relevant MeSH terms:


Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia	Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 28, 2017

To Top